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The Effects of Prenatal Amphetamine Adminis-

tration on Activity and the Levels of Brain Catecholamines in Young
Mice.

(Under the direction of John W'. Zemp).

CS7I3L/6Jmicc were injected with D-amphctamine sulfate for
the last six days of gestation.

Their offspring were compared with

those of saline -injected and untreated controls.

Although the amphet-

amine -treated mothers gained less weight than controls during treatment and three days post partum, this did not affect litter size or
body or brain weight of the offspring at birth.

Injections of either

drug or saline altered the rate of weight gain for the first month.
The offspring of the a.mphetamine-treated mothers had lower
levels of brain norepinephrine on the day of birth and higher levels of
norepinephrine and dopamine than either control group on day 30.
Their open field activity was higher than either control group on
day 22, but jiggle platform activity was lower than saline controls

at all times studied.

The catecholamine levels of saline -injected

controls were higher than those of untreated controls at days 21 and

30.
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INTRODUCTION

Amphetamines are popular members of the current drug scene,
being used by both young people and adults.

They have been implicated

in creating a paranoid and delusional state during which acts of pe rsonal
violence are cOnlm.itted (4) and in being causally associated with congenital heart disease when used during pregnancy (71).

Methylamphet-

amines have been im.plicated in the development of necrotizing angiitis
in adults (25).

The Food and Drug Adrn.inistration has recently re-

stricted use of arnphetarn.ines to treatment of narcolepsy, hyperkinetic
children, and exogenous obesity as a short term. (few weeks) adjunct

for weight control (3).
The mode of action of amphetamine in the brain has been
studied in adult organisms.

A.mphetaITline effects are m.ediated

through effects on the adrenergic synapses I i. e., those involving

the neurotransmitters dopamine (DA) and norepinephrine (NE) (43,
51, 101).
The parent amino acids 'for catecholatnine formation are
phenylalanine and tyrosine..

Phenylalanine is para-hydroxylated

to form L-tyrosine (Fig. I.). Tyrosine is meta-hydroxylated in the
presence of oxygen, tetrahydrobiopterin, NADPH, and the enzyme
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Figure I.

The Metabolism. of Tyrosine.

dopa.rnine and norepinephrine.

Tyrosine is metabolized to

These catecholam.ines are in turn

converted to their m.ethoxy metabolites via COMT.
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tyrosine hydroxylase to foral 3, 4-dihydroxyphenylalanine (L-DOPA).

Dopa decarboxylase, in the presence of pyridoxal phosphate and hydrogen ions, will convert DOPA to DA.

DA can be

S -hydroxylated to

form NE by the relatively nonspecific enzym.e doparnine- S -hydroxylase.

This enzyITle requires ascorbic acid, fUlUaric acid, and oxygen for
activity.

Doparn.ine - S -hydroxylase is bound to the rnelUbranes of the

catecholaITline storage vesicles (421 44, 101, 105 1 116).
In the conversion of tyrosine to L-DOPA, tyrosine hydroxylase
is subject to feedback inhibition by elevated levels of NE (63).

There

is also some secondary control of NE formation at the level of
dopamine- S-hydroxylase (113).
The catecholarrlines are m.etabolized intraneuronally by
monoamine oxidase (MAO), a m.itochondrial enzyrn.e that deaminates
the catecholam.ines.

Another enzynle, catechol-O-methyl transferase

(COMT), is present primarily in the extraneuronal space and
O-m.ethylates the active catecholamines in the lTIeta position (II, 42,

83, 116).
DA and NE are localized in specific areas of the brain.

The

principal brain DA tract at least partially originates in the pars corn.pacta
of the substantia nigra with nerve terminals in the corpus striatum., a
brain region as sociated with motor coordination (5, 16, 32, 37, 54, 78,

91, 99).

The ventrolTIedial nucleus _0£ the hypothalamus is rich in DA

terminals also and is implicated in gonadotropic levels and food intake
(54 ).
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A large part of the NE in the cerebral helTIispheres and diencephalon is derived from neurons corning from or passing through the

lTIcscncephalon.

The ITlajor NE tracts in the brain have their perikarya

in the brain steITl with axons ascending via the median forebrain bundle.

These tracts have nerve endings throughout the brain.

The highest con-

centration of NE is in the hypothalarnus and the limbic system. (5, 16,
23, 27, 54, 74, 78, 91).
In adult rats the NE levels of the hypothalamus average about

1.75

lJg/g with the rem.ainder of the brain areas showing lesser

aITlounts.

The corpus striatum contains approxirnatel y 5

the highest level of this monoam.ine in any brain area.
about.3

lJg/g of NE and. 7

67, 74, 81, Ill).
rats and mice.

lJg / g of DA,

Adult mice have

lJg/g of DA in the whole brain (16, 19" 21,

A wide range of values has been reported for both

The species of the animal and the analytical rnethod

used could be responsible for these variations in tissue levels.

For

all species studied" however, the relative amounts of catecholarnines
in various areas of the brain are consistent.
NE and DA levels in the m.ouse and rat brain are initially low
and gradually increase with age.

• J5J

Wg of NE per whole brain.

In rats 12 days of age, there are
By 24 clays of age there arc. 397

lJg and. 510 lJg of NE and DA, respectively, per whole brain ·(88).
In mice the level of NE reaches adult values by approximately 30 days
of age.

Adult levels of DA are not obtained in the mouse brain until

much later (1).
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A number of studies have been aimed at determining a relationship between the levels of DA and NE and the behavior of experimental
animals.

DA seems to be involved in stereotyped behavior (35, 55, 79,

80, 87, 91, 114) and possibly in hypermotility (9, 106).
Stereotypy in rats and mice consists of licking, sniffing, biting
cage bars, and backward locomotion at times, or sitting with hunched
backs.

Forward locomotion, eating, and grooming are absent (37).

In humans stereotyped behavior consists of normal movements, such

as arm rubbing or leg swinging, continued for prolonged periods (91,
III ).

When reserpine is given to animals, brain NE and DA are
depleted.

Even with the MAO inhibitor nialamide, NE, normet-

anephrine, DA, and 3-0-methyl dopamine are undetectable.

When

amphetamine (10 mg/kg) is given after the reserpine and nialamide,
levels of 3 -O-methyl dopamine increase to measurable amounts and
characteristic stereotypy is observed (79).

This same dose of D-

or L-amphetamine sulfate injected subcutaneously 1 hour before
intraventricular injection of 3H - DA brings about no change in the
endogenous DA levels in the corpus striatum, but the uptake of 3H-DA

is lowered.

Stereotypy is again observed (112).

DA injected iontophoretically into the area of the caudate
nucleus will cause spike rate depression or facilitation in those
caudate neurons in which depression is produced by electrical stim-

ulation of the substantia nigra (84).

Bilateral intrastriatal micro-
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inj<:ctions of l)A or p-hyc1roxyamphetarninc lead to stereotyped behavior.
Injections of NE into the same areas have no effect (37).

Elevated

levels of brain DA can aid in protection against audiogenic seizures
in mice (19).

The involveITlent of DA systems in stereotyped behavior

in hUITlans is illustrated by the prevention of such behavior by
haloperidol in Gilles de la Tourette's disease and by some side
effects of L-DOPA used an antiparkinsonian agent (91, Ill).
NE is thought to be involved in locomotion and aggres sive
behavior (79, 101, 106, 117).

NE that is released by reserpine is

inactivated by MAO inside the neuron (58).

There is an increase in

3 -ITlethoxynorepinepherine .metabolites with neurotransrnis sion or
electrical stiITlulation involving NE pathways (61).

Amphetamine

administration results in a decrease in endogenous NE levels and an
increase in methylated metabolites of NE and DA (10, 94, 112).
Arnphetarnine may work by MAO inhibition (12, 18, 43, 83),
direct receptor action (89), synaptic release of NE and DA (51, 94),
~

inhibition of catecholamine reuptake (42, 51, 83, 94, 112), and/or
inhibition of dopaITline - S -hydroxylase (43).
tyrosine (

a,

Work done using

a,

-methyl

-MT) or H44/68, inhibitors of tyrosine hydroxylase; FLA-

63, inhibitor of dopamine- B -hydroxylase; and reserpine have shown
that amphetamine is dependent on a continued biosynthesis of the
catechola:mines for action.

At low doses of amphetamine ( <1 m.g/kg)

the stores may be able to supply the catecholamines for activity (101,
104, 119).

Levels of brain NE increase with low doses of amphetamine,
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probably due to the release of feedback inhibition of tyrosine hydroxylase (61).
It has been reported the D-arnphetarnine antagonizes the effect
of

a-MT in a stimulus dependent situation by retarding the decline of

brain catecholarnines (70, 84, 114).

Recent work has shown that DA

present in the predominately NE areas of the brain is used for NE
synthesis.

Antagonism of the effect of

a-MT may be due to a

conversion of the DA present in the noradrenergic neurons to NE with
a subsequent initial decrease in the DA levels followed later by a
lowering of NE levels (113).
When a.mphetarnine is administered to an organism, it is

metabolized
(90).

9Y

oxidative deamination OJ lJY.Qr~~....ftJjY.JJJlfJ~~)

Amphetamine is taken up and concentrated in the brain very

rapidly in cOITlparison with other tissues (12, 22).

It is possible

that amphetamine can not be taken up into the dense core vesicles ,
which contain dopamine-

~

-hydroxylase, but must be p-hydroxylated

to p-hydroxyarnphetamine first (100).
precedes

It is known that p-hydroxylation

B -hydroxylation in biological material (22, 46, 90, 105).

Para-hydroxyarnphetamine and its glucuronide can be excreted by the
organism Or the p-hydroxyarnphetam.ine can be taken up by the dense
core vesicles and rapidly converted to p-hydroxynorephedrine by
dopamine- S -hydroxylase.

Para-hydroxynorephedrine remains in

the tissues for longer periods than amphetamine indicating that it can
be incorporated into the storage granules (46).

Para-hydroxynorephedrine,

Figure II.

The Hydroxylation of AITlphetamine.

A.mphetaITline is

hydroxylated first in the para position and then in the

S position to

form. the false neurotransITlitte r p -hydroxynorephedrine.
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like NE, can be depleted froIn the dense core vesicles with successive

doses of amphcta:minc or by reserpine (22).
from the brain in about 16 hours.

A:mphetarnine disappears

Para-hydroxynorephedrine is still

present 48 hours after a single dose of amphetam.ine (S rng/kg).

The

sustained decline of NE from the brain is due to the form.ation and
storage of p-hydroxynorephedrine in the dense core vesicles (10, 22,

46, 105).
Stein and Wise (95, 96, 97 t 98) have found an increase in the
methylated NE metabolites in the hypothalamus and am.ygdala following rewarding m.edial forebrain bundle stimulation.

Amphetamine

(3 mg/kg) caused an increase in the labeling of the amygdaloid

perfusate following intraventricular injection of 3H - NE but no increase
in the hypothalamic perfusate, unlike rewarding stimulation.

A 3-fold

increase in radioactivity did occur in the hypothalamic perfusate when
14C_DOPA was used with amphetamine.
Behaviorally in adults, amphetamine increases lnotor activity
(motility) as .measured by an ANIMEX activity detector (63, 106).

A

dose response curve of locomotor activity was observed in an activity
cage using photocells for detectors.

There was progressive enhance-

ment of locomotor activity as measured by this type activity box up to
1.5 mg/kg of D-amphetamine with decreasing locomotion and increasing stereotypy beyond this dosage (112).

Dextro-amphetamine sulfate,

S mg/kg, causes a decline in brain NE levels and a slight increase in

brain DA levels in adults.

Behaviorally this dose of amphetamine
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produces locomotor activity at about 500/0 of the maximally effective dos e.
This is also the EDSO for com.pulsive gnawing behavior (23, 89, Ill).
Olds (72) reported the effect in rats of several stimulatory drugs
on food consu.mption and instrumental responding (bar-pressing) for

food.

An1phctalninc treated anirnals ingested the same arn.ount of food

as nornlals but responded at higher rates for food reward and for longer

tilncs during extinction of the response.
Alpha-rn.ethyl tyrosine lowers endogenous levels of brain NE.
Six hours after a single

a. -MT injection the response rate on a con-

tinuous avoidance task was greatly reduced.
ment a rat functions normally on the task.
rat chronically pretreated with
continuous avoidance.

Following chronic treatArn.phetam.ine given to a

a-MT causes a decrease in levels of

This is possibly explained in terms of denerva-

tion hypersensitivity in that the animal readjusts to these new, lowered
levels of NE.

The NE released by the amphetamine would lower the

endogenous levels to the point that depression would follow (67).
The biochemical and behavioral changes noted using amphetamine
could seem to imply some corollary between the two parameters.

Pre-

natal stress in the form of maternal foot-shock (53), handling (13, 30),
undernutrition (2, 88), and drug and monoamine ad.ministration (15, 26,
41, 45, 86, 121) has been shown to induce both short term and prolonged
changes in catecholamine levels and/or activity in the young organism.
Coyle and Axelrod (31) have recently shown

th~t

in the brain the NE uptake

mechanism and the initial increase in the endogenous NE level occur on
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the seventeenth and eighteenth days of gestation, respectively. Amphetamine given during the last 6 days of pregnancy in the mouse could
affect either or both of the newly developing proces sese
The reserpine sensitive catecholamine s·::orage ITlechanism beCOInes functional after birth and increases with time (31).

If the

initiation of catecholam.ine storage is dependent on early NE uptake,
early alterations in uptake or endogenous catecholamine levels could
lead to modified levels at later times.
It was the purpose of this investigation to determine whether
administration of 5 rng/kg of D-am.phetamine sulfate, a dosage having
the biochemical and behavioral effects previously described, during
the last 6 days of gestation would produce modifications in the NE and
DA levels and generalized m.otor activity in the offspring.

Corellations

between brain catecholamine levels and behavior were studied.

MATERIALS AND METHODS

Experimental Procedure - Pregnant C57BL/6J mice (The Jackson Laboratory, Bar Harbor, Maine) were divided into three groups:
. imental, saline control, and untreated control.

exper-

All animals were

housed in separate plastic cages with regular mouse chow and water

ad libitum.

Each mouse was weighed daily during the last 6 days of

pregnancy_

The experimental group was injected daily with 5 mg/kg

of D-amphetamine sulfate (Smith, Kline. and French) in a 1 mg/ml

• 90/0 saline solution.
5 ml/kg of .90/0 saline.

The saline control mice were injected with
The untreated controls received no injections.

The drug or vehicle was given intraperitoneally using a standard
1 ml tuberculin syringe between 10:00 a. m. and 12:00 noon each day.
The injections were discontinued on delivery with the last

injection approximately 18 hours before delivery. The mothers were
weighed until weaning of the pups at 21 days of age.
Litters were sexed and culled to six pups, note
any dead, discolored, or malformed pups.

bei~g

made of

The pups were weighed

daily until sacrificed.
Food and water intake for each cage was recorded beginning with
the first injection day and continuing through sacrifice of the pups.
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The pups were sacrificed at 0, 3, 7 t 14, 21, and 30 days of
age.

When possible the O-day sarrlple consisted of 6 brains, the

3 -day sarrlple used 5, the 7 -day used 3, and the 14-day had 2 brains
per saITlple.

The others were made of 1 brain per sample.

After

decapitation the brain from the base of the m.edulla oblongata and
minus the olfactory bulbs was rapidly
on ice.

removed~

weighted, and placed

The brains were placed in labelled vials and stored in a

-18 0 C freezer until used for catecholamine as says.

Freezing for

up to 2 weeks had no effect on catecholamine levels when kept at this
temperature

(Table I, Appendix).

Preparation of the Alumina - The method of Anton and Sayre (6) was
followed for the acti vatio n of the aluminum oxide.

One -hundred grams

of aluminum. oxide (Woelm Neutral Activity Grade I) in 500 Inl of
2 N hydrochloric acid (Hel) in a covered liter beaker were stirred
and heated to 90-100° C for 45 minutes.

The suspension was removed

from the heat and allowed to settle for 1~ minutes.

The yellow super-

natant and finer alulTIinum oxide particles were removed by aspiration.
The remaining alumina was washed twice with 250 rol of 2 N HCl at
70° C for 10 minutes.
discarded.

The supernatant and finer particles were

The alumina was washed about 25 times with 200 ml

portions of deionized water until a pH of 3.4 was reached.

The su-

pernatant and finer particles were discarded after each wash.

After

the last wash, the aluminum oxide was transferred to an evaporating
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dish and heated for 1 hour at 120
stored at 37

o

o

C, 2 hours at 200

0

C, and then

c.

Saluple Preparation - Samples we re prepared by the method of Anton
and Sayre (6) with modifications by

Boggan>:~.

Brains were removed

from the freezer and allowed to thaw for 2 minutes.

The tissue was

homogenized in 20 ml of cold 0.4 N perchloric acid (peA) in a PotterElvchjCITl homogenizer with a Teflon pestle using 5 strokes at a pestle

speed of 8 as marked on a Tri-R Stir-R motor.

The hO}nogenate was

transferred to a cold 30 ml Corex tube and centrifuged in a Sorvall
SS-34 rotor at 30,000 x g for 15 minutes at 4

0

C.

The supernatant

could be stored for several hours or frozen for at least 24 hours if
the procedure could not be continued immediately.
To a 100 ml beaker for each sample was added 400 mg of
activated alurrlinurn oxide and 5 ml of deionized water containing
200 mg disodium ethylenediamine tetra-acetate (EDTA) and 10 mg
sodiulTI-rrleta-bisulfite freshly prepared.
Ice.

The beakers were kept on

The cold sample was added "to each beaker just before neutralizing.

Norepinephrine base (Sigma), 1.5 ng and 1 ng of dopamine base (Sigma)
in 20 rnl of 0.4 N peA were also added to one beaker to check for recovery.

The samples were adjusted to pH 8.6 using 2 N Tris.

Samples were stirred with a 6-unit m.ulti-stirrer in 4 sample units.

~:(,w.

O. Boggan 1970: personal com.munication.
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The 4 rnicroelectrodes were connected to a Beckman Digital pH meter
set at 15
minutes.

o

C.

After reaching pH 8. 6 the samples were stirred for 5

Use of magnetic stirrers caused grinding of the alumina.

After 5 minutes the samples were removed and placed on ice
until all the samples were neutralized.
The supernatant was aspirated and the alumina was washed into
15 ml culture tubes witb scre'W-on t-ops using 1 D L221 of deionized W"at-er.

The tubes were shaken

On

a rotary stirrer at a speed of 2 for 2 minutes.

The tubes were then removed, tapped gently on the bottom and sides,
and allowed to settle for 3 minutes.

The water was aspirated and

discarded and the washing was repeated 3 times.
The catecholarnines were eluted in 3 ml of 0.05 N peA by
shaking at high speed for 15 minutes on an Eberbach shaker.

Catecholamine Assays - For the NE assay 0.3 ml of 0.5 M phosphate
buffer (adjust aIM solution of KH2P04 to pH 7.0 using 1 N sodium
hydroxide (NaOH) and dilute with deionized water to O. 5 M) was added
to a 13 x 100 mm test tube for each sample.

A 0.6 ml aliquot of each

sample was transferred to the appropriate tube of buffer and shaken
welL

A 0.6 rnl aliquot of 0.05 N peA was also added to a tube for

the blank.

The Perkin-Elmer spectrofluorometer was adjusted to 80

using Fluorescein, 150 ng/ml, at a sensitivity of 3, activation slit of 5,
ernis sion slit of 16, activation wave length of 410 nm, and emis sion
wave length of 520 nrn.

The remainder of the solutions were then

prepared (see below) and the assay continued.
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To the sample-buffer mixture was added 0.06 ml of freshly prepared 0.25 0/ 0 potassium ferricyanide and the solution was stirred on a

Vortex mixer.

After 1 minute, oxidation was stopped with the addition

of 0.6 ml of freshly prepared alkaline ascorbate (dissolve 100 m.g of
ascorbic acid in 1 ml of deionized water, add 0.2 rnl of this solution
to 10 ml of 10 N NaOH, and stir thoroughly).

After stirring water,

0.5 ml, was added to prevent crystallization and mixed thoroughly.

Samples were read immediately.
A standard curve was prepared initially by setting the inst.:u-

ment to 80 as described, then running 4 samples at each 100, 200,
and 400 ng of NE base/O. 6 ml of 0.05 N peA.

The averages of these

concentration assays gave a linear plot extending through zero and
having a sensitivity of 1.9 ng.

Sample values with the blank sub-

tracted were read from this plot.

The NE recovery averaged 750/0.

The DA assay was similar to the NE assay.

Two-tenths ml

of 0.5 M phosphate buffer (as described for the NE assay) was added
to a 13 x 100 rom test tube for each sample.

A 0.4 ml aliquot of each

sample and 0.4 rol aliquot of O. 05 N peA for the blank were added to
the appropriate test tube and stirred.
adjusted to 80 using 20

The spectrofluorometer was

II M quinin~ sulfate J sensitivity of 1, activation

slit of 5, emission slit of 14) activation wave length of 335 nrn, and an
emission wave length of 390 nIne

To the buffer-sample mixture was

added O. 04 ml freshly prepared O. 50/0 sodium periodate (make in a
volumetric flask) and mixed on the Vortex mixer.

One minute later,
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0.2 rn.l of freshly prepared alkaline sulfite (dissolve 125 m.g anhydrous
Na ZS03 in 0.5 ml of water, add 4. 5 rnl of 5 N NaOH and m.ix thoroughly)

was added and rnixed on the Vortex.

Water, O.56rnl, 0.2 rnl of 0.5 M

citrate buffer (adjust a solution of 1.0 M citric acid to pH 4.0 with
10 N NaOH and dilute to 0.5 M with water), and 0.34 rnl of 3 M
phosphoric acid (make daily) were added and tnixed by shaking on the
Vortex.

Samples were read im.m.ediately.
A standard curve was prepared as for the NE.

were prepared in terms of the free base.
obtained.

The standards

A sensitivity of 8 ng was

The DA recovery averaged 600/0.

Psychological Studies - For the psychological studies the litters were
culled at delivery to 4 pups, 2 m.ales and 2 females where possible.
On days 12, 15, 18, 21, and 30, two pups frorn each litter
were tested for five minutes on a Lehigh Valley Electronics jiggle
platform enclosed by a 22 x 18 x 12 dark, soundproof box.

The mouse

was placed in a cylindrical plastic container 5. 5 inches high and 7. 75
inches across.

The saIne two pups were used on each testing day and

were distinguished by ear punching the right ear on day 12.

The

activity counts were recorded for each minute of the total five minute
testing tim.e.

The plastic container was dried and cleaned of any

fecal boli after each m.ouse.

The mice were tested between 9:00 a. m.

and 12:00 noon of the testing days.

18
On days 13, 16, 19, 221 and 31 the pups used on the jiggle platfor.m were tested in a 16 x 16 x 4 inch open field activity box.

The box

was ITlarked off into 4 x 4 inch squares and a lTIouse was counted as
entering a square if he placed two feet across the line marking a
square.

A plexiglass cover was used to prevent the mouse froITl jump-

ing onto the sides or out of the box.

The mouse was observed for 5

Ininutes with the number of squares entered per Ininute recorded.
The weights of the mothe r until weaning at day 21 and the
weights of the individual pups was recorded from day 0 through day
3 O.

RESULTS

Results are presented for the am.phetamine (DAMS), saline
control (SC), and untreated control (UC) groups.
statistical analyses were used:

Two types of

the two-tailed t-test and a least

squares analysis using a modified~:~ BMDX64 program from the UCLA
Biomedical Co.mputer Program.s run on an IBM 360/40 cOnlputer.
The least squares analysis compared, where applicable, group,
tiITle, and sex effects.

The pattern of change over time by the groups

(group by time), group changes according to sex (group by sex), and
changes over time according to sex (time by sex) were also determined
by this analysis.

Maternal Weights - Table I. presents data for the weights of the mothers
from the start of the injections to delivery.
significant difference (p

There was a statistically

< .05) in the body weight of the DAMS females

beginning 4 days before delivery (D-4).

D-3 showed no statistical weight

difference but the mean for the DAMS was lower than that of either the
';-C or the SC groups.

The weight difference continued for at least 3

da" s post partum (Table II. ).
,roO
'f·

e.

B. Loadholt 1971: personal communication.

Table I.

Maternal Weights in GraITls from the Beginning of Injections to

Delivery (BiochclUical Study).

Mean ITlaternal weights in grams are

given for a.mphetarnine (DAMS), saline (SC), and untreated (UC) groups.
The DAMS ITlothers received a daily injection of 5 mg/kg of D-amphetamine sulfate beginning 6 days prior to delivery (D-6) and continuing
through delivery.

The SC animals received 5 ml/kg of .90/0 saline

daily during the same period.
during pregnancy.

The DC mothers received no injections

The litters of these animals were culled to 6 pups

and were used for the biochemical studies.
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Treatment

SC

DAMS

UC

Day
D-6

26.6+1.4

27.3+1.8

27.8+3.1

D-5

27.3+1.7

28.5+1.9

28.7+3.7

D-4

28. 4+2.

30.2+2. 2

30.4+4.0

D-3

29.8+1.9

31.9+2.0

32.3+4.3

D-2

31. 2+2. 2;::c

33.6+2.2

34.2+4.5

D-l

32. 8+3. O;::~

34.8+2.6

36.0+4.4

23.7+2.1

24. 6 +1. 7

24.7+2.2

N = 16

N = 11

Delivery

N

= 14

Mean

Table III

O~:~

+ S. D. M.

jVfaternal Weights in Grams from the Beginning of Injections

to Delivery (Biochemical Study).

Table II.

Maternal Weights in Gram.s from. Delivery to Weaning of the

Pups at 21 Days (Biochemical Study).

Mean m.aternal weights in grams

are given for DAMS, SC, and DC groups for 3-21 days post partum.
These are the same animals described in Table I.
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Treatment

DAMS

SC

DC

Day
Delivery

23.7+2.1(14)
"I"

24.6+1.7(16)

24.7+2.2(11)

3

24.4+2.1""(10)

25.9+1.9(13)

26.8+2.6(10)

7

27.3+1.0(7)

27.4+2.1(10)

28.2+2.9(7)

14

30.4+1.3(5)

29.4+3.5(6)

30. 9+2. 5(6)

21

26.9+1.1(5)

26. 7+2. 4(6)

28.9+2.1(4}

Mean + S. D. M. (N)

Table II.

"I"

""(p < • 0 5)

Maternal Weights in Gram.s from Delivery to Weaning of

the Pups at 21 Days (Biochemical Study).
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Although the DAMS mothers gained less weight during pregnancy,
the litter size was not affected by the drug or vehicle ad:tninistrations.
DAMS averaged 6.4

of an average 6.7
per litter.

+ 1.8

+ 2.1

pups per litter, the SC group litter consisted

pups and the DC group averaged 6.6

+ 2.

1 pups

These litter sizes are not significantly different.

The weights of the mothers of the pups used in the psychological
studies were recorded separately to check for any maternal weight
changes resulting from. the handling of the pups (Table III. ).

No

weight difference was noted between drug and control groups of mothers
nor was there a difference between the maternal weights of the biochernical group and the psychological group.

Food and Water Consum.ption - Food and water consumption per day
per cage per gram m.aternai'weight was obtained beginning with the
initial treatment day and continuing through weaning of the pups
(Table IV.).

The weight of the pups was not us ed ip these calculations.

It was believed the pups did not consume food pellets and water until
their eyes opened and even then the amount was not appreciable
considering the lack of weight change for the pups for one or two days
after weaning and low food and water consumption per pup at the same
tin'lc.

There was no statistically significant difference between either

of the three groups using the two-tailed t-test.

Thus, even though the

DAMS animals gained less weight, the food and water consumption per
gram was equivalent to the other two groups.

Table III.

Maternal Weights in Grams from Day 12 Through Day 21

(Psychological Study).

The body weights of the mothers of the pups

used in the psychological testing showed no group differences or group
by tim.e interactions.

No differences in body weight were noted between

the ITlothers in the psychological study and the mothers in the biochemical study.
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DAMS

SC

DC

12

28.3+1.4

28.4+1.9

28.1+1.7
-

13

28.8+1.4

-

28.0+2.2

28.2+1.6
-

14

29.5+1.3

28.7+1.3

28.6+1. 5

15

28.4+1.6

28.2+1.3

27.8+1.3

16

28.8+2.1

28.1+1.7

27.2+1.0

17

3 o. 1 +2. 6

27.5+1.5

28.1+1.7

18

28.5+2.4

27.5+1.5

27.4+1.1

19

27.5+2.7

26.7+1.5

27.2+0.8

20

27. 9+2. 3

26.0+1.5

27.1+0.7

21

27.1+2.2

25.9+1.5

26.2+1.3

Group
Day

N"= 6

N

=5

N

=6

Mean + S. D. M.

Table III.

Maternal Weights in Gram.s from. Day 12 Through Day 21

(Psychological Study).

Table IV.

Food and Water Consum.ption per Cage frolU the Initiation of

Injections to Weaning of the Pups.

Food and water consumption per cage

per gram maternal weight are given beginning with the first injection
day (D-6) and continuing through day 21.

Water is expressed in m.l/g

body weight and food is given as g / g body weight.

SC

DAMS

Group

DC

Day

Water
mJ/g

Food
gig

W-ater
ml/g

Food
gig

Water
ml/g

Food
gig

D-6

.25+.07

. 13+. 04

.23+.06

· 14+.02

.25+.06

· 16+.03

D-5

.23+.05

.15+.05

• 22 +. 04

.15+.03

.24+.03

· 14+. 04

D-4

.22+.04

.16+.04

.21+.04

.17+.05

.21+.03

.19+.04

D-3

.23+.04

.16+.04

.21+.05

.16+.03

.22+.02

.17+.03

D-2

· ZI+. 04

.15+.03

.17+.04

.13+.05

.18+.03

· 14+. 03

D-1

.26+.05

.19+.05

.22+.06

.18+.10

· 2Z+. 05

.13+.02

Delivery

• 34+. 07

.25+.06

.29+.05

.21+.06

· 34+. 09

· 23+. 04

3

.41+.06

.37+.08

.32+. 07

· 28+. 06

.31+.09

.25+.07

7

.47+.11

.37+.12

.44+.10

· 36+. 07

.43+.05

.34+. 09

14

· 68+. 09

.40+.10

.53+.20

· 34+. 05

.65+.06

.36+.10

21

.49+.16

. 16+. 03

.30+.01

· 17 +. 04

· 39+. 08

.18+.04

-

Mean
Table IV.
the Pups.

+

S. D. M.

Food and Water Consum.ption per Cage from the Initiation of Injections to Weaning of
N
~

fl'
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Pup Weights - Figure III. and Table II. of the Appendix show the pup
body weights for the three groups in the biochemical study.

Using

the two-tailed t-test, there was no statistical difference on any gi ven
day, but there was a group difference (p <

interaction (p <

.01).

.025) and a group by time

Since the differences were only noted using

the least squares analysis, the group and group by time changes
would indicate that the pattern of weight gain over time for the three
groups differed enough to produce statistical changes.
A statistical difference in weight was also noted by sex (p <

• O~S).

The females weighed the same as the males at birth but were smaller
than the males at day 30 in all groups.
The weights of the pups used in the psychological studies were
tabulated separately to check for any effects of handling (Table V. ).
At all ti.mes the DAMS pups weighed statistically les s than the other
two groups with the exception of days 17 and 18.
also weighed less than the DC group.

On day 30 the SC pups

Whether the statistical differences

were due to handling or a combination of handling stress and other
factors is unknown.

The weight difference could be due to a reduction

in ITlaternal care and food supply due to the litter size.

It could be that

the slYlaller litter size accentuated any difference in weight caused by
the drug or the injection.

This effect would then have been obscured

in the larger litters of the biochem.ical studies.
In Table V. a plateau in weight gain from appr.oxim.ately day 16
to day 19 can be seen.

It began just after the eyes opened and continued

Figure III.

Body Weights in GralnS from Birth to 30 Days of Age for

Pups Used in the Biochemical Study.

The body weights for the ex-

perirrlental (DAMS) and the 2 control groups (SC and DC) are given
for each experimental day from birth to 30 days of age.

The litters

were culled to 6 animals and the pups were weighed each In.orning.
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14
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Body Weights in Gram.s from Birth to 30 Days

of Age for Pups Used in the Biochemical Study.

Table V.

Body Weights in Grams from 12 to 30 Days of Age for Pups

Used in the Psychological Study.

The body weights for the 3 groups of

animals are given beginning with the first day of experimental work and
continuing through day 30.

The pups were tested on days 12, 15, 18,

21, and 30 on the jiggle platform and on days 13, 16, 19, 22, and 31
in the open field maze.

The litters were culled to 4 pups at delivery.
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Group

SC

DAMS

UC

Day

12

6. 7 +O. 8 ~::: ~::: * (24)

13

7 . 2 +O. 8 "I~ 'I~

7.2+0.8(20)

7.7+1.2(21)

24)

7. 8+0. 9(20)

8.3+1.3(21)

14

7. 7+0. S ..·"I'· ....· (24)

8. 2+0. 9(20)

8. 7 + 1. 3 (21)

15

8. 3 +0. 8 ..·' ..·....,.. (22)

8.6+0.9(19)

9.2+1.4(21)

16

8.6+0.9""(22)

8.8+0.9(19)

9.4+1.3(21)

17

8 . 8 +0. 8 (2 2 )

9. 1 +0. 4 (19)

9.5+1.4(21)

18

8 . 9+0.9(22)

9. 0+0. 9(19)

9. 6 + 1. 3 (21)

19

8.9+0.9*(22)

9. 0+1.0(19)

9. 7 + 1. 4(21)

20

9. 4+0. 9>::: (22)

9. 4+ 1. 1 (1 9)

10.2+1.4(21)

21

9. 9+0. 9'* (22)

9. 9+0. 9( 19)

10. 8 + 1. 6 (21)

30

15. 9+0.8*>:(20)

16. 0+2. 1 *(17)

17.8+2.7(19)

........ "" ........~
"I' (

...,-' -..''''''' .....f'''

,1... '-'J- ....f...

..1#

Mean

+ S. D. M.

(N)

>:(

(p <

*):( (p
--. ..t..>,;>",
.. ,..... (p

Table V.

?

•

< •

05)

02)

< • 01)

Body Weights in Grams from 12 to 30 Days of Age for Pups

Used in the Psychological Study.
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until just before weaning.

The pups might be requiring more milk than

the ITlother can supply and the pups are gradually starting to eat and
drink for thernselves.

The pups did continue to nurse until weaned

and then Inaintained another, shorter-term plateau, as previously
ITlentioned, just after weaning.

Brain Weights - Pup brain weights (Fig. IV. , also Appendix Table III.), unlike pup body weights I

show no group differences.

The brain weight gain pattern for the groups did show a group by
tirne interaction (p <

.005).

Initially the 3 groups had a brain

weight approximately the sarne, but by day 7 the DC brain weights
were higher than the other 2 groups.
the pattern reversed.
DAMS, and DC.

This continued until day 21 when

At day 30 the order from. high to low was SC

t

This is the sam.e order as the body weights at day 30.

Sex als 0 affected the b rain weight (p <

• 005), but the re was

no time by s ex effect.

Norepinephrine - The brain NE values are given in Fig. V. and Table
IV. of the Appendix.

Both NE and DA are expres sed on a per brain

basis to exclude any effects due to changes in total cell number or
changes in the number of cells containing the m.onoam.ines (88).
NE levels were also calculated in terms of per graIn brain

J

The

however,

and are listed in Table V. of the Appendix.
In Fig. V. a statistically significant, low level of NE can be seen
in the DAMS at day 0 as compared with the DC.

This is not unexpected

Figure IV.

Brain Weights in Grams from Birth to 30 Days of Age for

Pups Used in the Biochemical Study.

The brains, minus the olfactory

bulbs, were weighed and frozen until assayed.
in grams wet weight.

The values are given

There was no statistical difference on any given

day, but the group by tim.e interaction was significant at the p < • 05
level.
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21

14

IN

30

DAYS

Brain Weights in Grams £roITl Birth to 30 Days

of Age for Pups Used in the Biochern.ical Study.

Figure V.

Nanograms of Norepinephrine per Brain. The norepineph-

rine per brain for the 3 groups studied showed an initially low level
and gradually increased with time.

The 'statistical differences were

obtained by comparing the DAMS with the UC and the SC with the UC.
There is also a significant difference (p < .01) between the DAMS
and the SC at day 30.
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Figure V.

Nanograms of Norepinephrine per Brain.
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since prolonged trcat.m.ent with amphetamine depletes NE (42, 94) and
suggests that there was some placental transfer of amphetamine.
levels are approximately normal by day 3.

The SC group is also lower

than DC group at day 0 but not statistically so.
an increase from. 0 to 30 days (p

<

.01).

The

All three groups show

On day 21 the SC group and

on day 30 both the DAMS and the SC groups show a significant increase
above UC values, with the DAMS showing a level roughly twice that of
the DC values (p
SC values also.

<

.001) and statistically higher (p

<

.001) than the

The group differences were significant at the p

level and there was a group by tim.e interaction at the p <

<

.01

• 01 level.

The values of NE/g brain parallel those of NE/brain.

The

changes in NE/brain or in NE/g brain do not parallel the weight gain
pattern for the three groups except at days 0 and 7.

This trend is

certainly not followed at day 30 when the levels of NE in the DAMS
group are much higher than the SC or DC and the SC brains are larger
than DAMS and UC.

Doparnine - The DA values (Fig. VI., also Appendix - Table VI. )
parallel those of NE except there is apparently no initially low level
in the DA1v1S group.

A slight but nonsignificant decrease occurs on

day 3 for the DAMS group.

This assay is not so sensitive (8 ng) as

the NE assay (2 ng), thus the greater variation at low levels.

On day

21 the SC and on day 30 both the DAMS and the SC groups have levels of
DA significantly above UC levels.
higher than SC at day 30 however.

The DAMS levels are not statistically

Figure VI.

.Nanograms of Dopamine per Brain.

The changes in levels

of dopaITline over tim.e parallel.ed those of norepinephrine; however, the

levels per brain at any given time were higher than those of norepinephrine.

The DAMS and the SC were compared with the UC group to obtain

statistical differences.

There was no statistical difference between the

DAMS and the SC groups at any time.
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The levels of DA/brain are listed in the Appendix - Table VII.
The change with ti,lTIC is significant at the p
effect is significant at the p

<

.05 level.

< • 01 level.

The group

The values per gra.m. brain

parallel those of DA /brain except the increase over time in the DAMS
group is ITlore exaggerated.

Psychological Studies - The jiggle platforrn activity scores showed
extreme variance at all times making analysis difficult using the raw
scores.

The medians, a measure of the central tendency of the

aniITlals, for the days studied:

12,' 15, 18, 211 and 30, indicated that

the DAMS activity level was lower than SC and UC on days 12-18.

The

DAMS .m.edian rose to a level higher than UC but lower than SC on day

21, and by day 30 the activity level for the DAMS anim.als had risen to
a value higher than SC and UC.

This trend was not substantiated by the

t-test due to the wide variance in the raw score values.
The anim.als used in the psychological testing consisted of 2
sets of animals born 2 weeks apart and each set consisted of DAMS,

SC, and UC anim.als.

Since the DAMS, SC,and DC ani.m.als from a set

were all run on the same day for a given experimental day, any variation due to the day to day changes in the jiggle platform. could be
eliminated by putting the DAMS and SC values in term.s of the mean of
the DC and expres sing the value as a percent of the mean of the DC for

the particular ti.m.e period (Fig. VII., also Appendix - Table VIII. ).

This yielded a group effect significant at the p <
no sex or time effect and no interaction effect.

.01 level.

There was

The values for the
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females were higher than the values for the males within a group, however, and the SC values were higher than DAMS values at all times.
The DAMS values were lower than UC levels at days 15 and 18.
Analysis of the open field activity revealed no group or sex
effects with the least squares analysis.

The t-test did reveal a dif-

ference at day 22 when DAMS levels were higher than SC or UC
(Table VI.).

The levels of activity did increase over time indicating

the Inicc became more active with age.

How long this trend of in-

creased activity continued was undetermined.

Table VI.

Open Field Maze Scores.

groups gave no group or sex effect.

The open field scores for the 3
The anim.als did become more

active with age, particularly between days 16 and 19.

This is the

time when their visual acuity has increased and the pups can see to
move about.

On day 22 the DAMS pups did show a statistical increase

in activity over the UC group, but at no other time did such a difference

occur.
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DAMS

SC

UC

13

29+18

34+24

32+23

16

58+49

59+31

42+50

19

130+75

121 +56

135+55

22

159+34'''-

144+34

131+17

31

165+34

178 +32

161+35

Treatluent

Day

..I,.

N

= 12

Mean

Table VI.

N

= 10

N

= 12

+ S. D. M.

Open Field Maze Scores.
/

CONCLUSIONS

D-Amphetamine sulfate (5 mg/kg) given to pregnant C57BL/6J
mice during the last 6 days of pregnancy caused a decreased weight
gain beginning 3 days after the initiation of injections and continuing
for at least 3 days post partum.

Food and water consumption per gram

did not differ among the 3 groups of mothers at any time from the beginning of injections through weaning of the pups.

At delivery the

litter size was no different for the DAMS, SC, and UC.

The offspring

had no difference in body or brain weight at birth or at any other time
in development.

The DAMS and SC groups did show a more rapid

increase in brain and body weight in early development, especially
between days 7 and 14, than the UC.

After 14 days the weight gain per

day slowed down and did not differ between groups.

The possible effects

of the amphetamine or the injection stress on the developing hypothalamus and pituitary gland could have induced the pattern of weight
change.

Amphetamine does affect areas of the hypothalamus and

midbrain that control the secretion of neuroendocrine releasing factors
for corticotropin and growth hormore (9, 17

t

107).

The DAMS pups

used in the psychological studies did have a mean body weight lower than
that of the UC.

The smaller litter size utilized in the psychological

study could possibly have caused reduced maternal care and hence,

38
sn"lallcr pups.

The DAMS pups in the psychological study did not differ

significantly in body weight froIn the DAMS pups in the biochemical

study, however.

Other studies have shown that D-am.phetam.ine sulfate

did not affect litter size or pup weight (26, 30, 41, 53).

A sex effect

\vas found but there was no statistical difference in brain or body weight
by sex at any tiIne.

A weight difference by sex has been noted in other

studies with the behavioral performance dependent on the sex of the
a nirnal (26, 45) .
In the present study it was found that the NE levels were higher

and the DA levels were lower in the UC mice at day 0 than in the study
by Agrawal and Hirn.wich (I).

The levels of both catecholam.ines in-

creased steadily through day 30.

At day 30 the NE levels reznained

higher and the DA rell1.ained lower than the levels given by Agrawal
and Hirnwich (1).

It is difficult to compare the values obtained in this

study with the values reported by other workers since the tiIne periods
chosen are often not the same and the strain of Inouse used is not
always specified.
While no values for catecholaIlline levels in young C57BL/6J
nlice have been reported, levels of NE of about 385 ng/g brain have
been reported for adult ll1.ale C57BL/6J Inice 70 to 100 days of age (81).
Boggan and Seiden (19) have found NE levels of 315 ng/g brain in 30 day
old DBA/2 !nice and 390 ng/g brain in 27 day old DBA/l mice. They also
found DA levels of about 617 ng/g in DBA/Z mice and 1000 ng/g brain in
DBA/l nUce.

These values compare favorably"with the 325 ng/g and the
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730 ng/g brain for the NE and DA, respectively, found in the 30 day UC
anin.lals in. this stud Y.

The low NE levels at day 0 in the DAMS group suggests that
SOITlC

placental transfer of amphetamine or its m.etabolites did occur.

Radioautographic studies using other psychoactive drugs have demon,I..

strated the placental transfer of such drugs"", so it is asswned some
forn.'1 of the alTIphetaITline is transferred in this case.

The low levels

of DA at day 0 agree with SOale reports on the effects of am.pheta.mine
(43: 89, 112).

The effect on the catecholamines is a dose dependent

response with BOlTIe disagreement as to the dose-response levels.

Low

levels of amphetamine cause an increase in NE and DA levels while
higher doses cause depletion.

The doses that cause the modifications

vary according to the species and the assay procedure (63, 112).
Coyle and Axelrod reported that the NE uptake and the increase
in endogenous NE begin on days 17 and 18 of gestation (31).

This is

during the time of the injections of drug and vehicle in this study.

The

day 0 levels of NE suggest that the drug has lowered endogenous NE
levels.

This could be due to a modification of uptake and/or to in-

creased release.

Amphetamine is known to block uptake of NE in

adult organisITls (42, 51, 83, 94, 112) and also to cause synaptic release of NE and DA (51, 94).

If the am.phetaITline had been taken up

by the neurons or at least had blocked the uptake or increased the

';:~w. J. Waddell 1971: personal cornm.unication.
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release of the catecholamine, the regulation of tyrosine hydroxylase
could have been lUodified.
bition by NE.

This enzym.e is regulated by feedback inhi-

Tyrosine hydroxylase levels also appear to be subject

to genetic control (11).

NE causes a repression of enzyme synthesis.

Shoemaker and Wurtm.an report that rats whose dams received a
protein deficient diet during pregnancy had decreased NE and DA levels
and increased tyrosine hydroxylase at day 24 (88).

The lowered levels

of NE at birth could cause not only increased levels of tyrosine hydroxylase but also increased tyrosine hydroxylase activity_

This increased

activity could lead to an overshoot of catecholamine levels by day 21
and 30.

That increased catecholamine levels do not appear until 21 to

30 days of age could be due to furthe r regulation of NE biosynthesis by
dopamine -

a -hydroxylase.

Modified levels of dopaInine -

a -hydroxylase

in the developing catecholamine storage vesicles could convert exaggerated all'lounts of DA to NE.
the levels of dopamineganglia.

Chronic reserpine treatrnent can cause

a-hydroxylase to increase

in sympathetic

This increase can be blocked by inhibition of protein syn-

thesis (11).
The total number of adrenergic neurons could also be increased.
No work was done to ascertain whether there was an increased cell
nwnber in the brain.
determined.

The turnover rate for NE and DA was also not

It is also possible that there were no enzym.e rnodifications,

but a change in the catecholamine turnover rate occurred.

There could

also have been an increased nuIllber of vesicles in each neuron with
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subsequent increased levels of NE and DA.

The atnphetarnine could

cause an increased nUlnber of the amine storage vesicles to be formed
and transported down the axon.

The increase in catecholamine levels at 21 and 30 days is also
consistent with increased axonal downflow of monoamine storage
vesicles with a life span of 3 to 4 weeks that has been reported in
rats after reserpine treattnent (48).

The 30 day time course is also

consistent with rates of slow axoplasrrric downflow of the storage
vesicles (14).
The elevated levels of NE and DA in the DAMS and SC groups
at day 30 could have been due to prenatal stress since both groups
were elevated above control. Footshock administered to a female rat
during pregnancy resulted in an increased NE turnover in the telencephalon-diencephalon area of the brain at 40 to 45 days of age.

In-

creased NE levels were also noted in the brain steIn-mesencephalon
area (53).

It seems that the stress of the injections to the mother

caused a change in catecholarnine levels on the young pup.
anline enhanced this stress effect.

Arnph~t

The .mechanism for the stress

effect is unknown and likewise it is unknown whether amphetamine

uses the same or a different mechanism to further increase the stress
effect on brain catecholarn.ine levels.
Activity studies were undertaken to determine if changes in
brain catecholamine levels would produce tneasurable changes in
locom.otor activity..

The jiggle platforIll. rneasured generalized

activity and the open field study measured ~ocornotor activity.
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The variance at all times and in all groups on the jiggle platform
prevented the raw data being used as a reliable .measure.

The central

tendency of the groups was consistent with changes in catecholamines
but the correlation was not statistical.

Day 30 jiggle platform. scores

would have been significantly higher (p

<

.05) than DC if the single

high value out of 12 animals in the DC group were dropped.

This one

high value was almost twice the value of the second highest score and
the remainder of the scores were closely grouped around the second
highest value.

Further work in this lab has shown that the offspring

of mice who were injected for longer periods of time with amphetamine
had activity levels higher than UC (p

<

.025) when tested on the jiggle

,f",

platform at 34 days of age "j~.
When the data is presented as the percent of the mean of UC
values, the resultant graph resembles an habituation curve.

The

values are initially high and gradually decrease then start to rise again.
The activity levels of the SC males and fem.ales on day 30 were lower
than their initial levels on day 12, but the DAMS .males and females
had values higher than their initial scores.
to the design of the experiment.

This could have been due

The anim.als were not handled from

day 22 to day 30 except for weighing.

The DAMS animals could have

been more sensitive to the trauma of the jiggle platform and the decreased handling from day 22 to day 30 e:rnphasized this sensitivity.

;;:~L. D. Middaugh 1971: personal corrununication.
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The reverse could be true with the SC animals being less sensitive.
Overall the injection stress could have increased activity levels and

the amphetamine antagonized the stress effect.
The correlation of activity with NE and DA levels is obscure.
The SC values were higher than but parallel to the DAMS at all times.
On days 21 and 30 for SC and day 30 for DAMS when there was a
statistically significant difference in NE and DA levels, there was only
a marginally significant difference in the activity levels.

At day 30

when the DAMS catecholamine values are elevated above the SC values,
the SC activity levels were still higher than DAMS.

If levels in specific

areas of the brain were obtained, the relation of catecholamine levels
to jiggle activity might be clarified.
The open field scores were alrnost identical initially and increas ed over tirn.e.
day 19.

The scores increased greatly from day 16 to

During this time the pups

f

visual acuity increased and their

exploratory behavior also increased.

Only on day 22 is there a

statistically significant diffe re nce in the scores.
the DAMS and the SC were higher than the VC.

At that time both
Clark et ale (26)

administered 1 rng /kg of D-arnphetarnine sulfate to pregnant rats from
days 12 through 15 of gestation.

The offspring were tested at various

times in an open field activity box.

The offspring of the arnpheta.rnine

}])~Jr9S.l..? E2~ }~:y _~~_t!:vitJ scores in the 0yen field test 21 days after

birth when compared to saline controls.

Since there is an anomalous

dosage effect of amphetamine on catecholamine levels, the higher activ-

ity levels with 5 rng/kg in our study is not unexpected.
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The open field values on day 30 could have been influenced by
the cxperilTIcntal design as were the jiggle platforll1. tests.
week of little handling, the

se

and

ue

After a

values increased above those

of day 22 while the DAMS values changed very little.

The jiggle plat-

form and the open field are measures of different types of activity and
therefore differing results are not unexpected.
It has been determined that aInphetamine caused a decreased
maternal weight gain, but had no effect on food and water consumption, litter size, and pup brain and body weights.
creased NE and DA levels at day 30.

There are in-

Behavior is also modified. The

increased brain catecholamine levels could be due to direct action of
arnpheta.m.ine or the injection stress on the biosynthesis of the
catecholantines and induction of the behavioral changes.

The increase

could be due also to a latent effect on the adrenal medulla to release
epinephrine and thereby change the brain catecholam.ine levels and
modify behavior (15, 17).
Regardless of the Ill.echanisrn by which the changes occurred,
this research has clearly dem.onstrated that the prenatal administration

of the central nervous system stimulant, amphetamine, has produced a

pronounced and significant change in the brain - a doubling of NE and of
DA at 30 days.

Saline control animals suggest that at least part of the

effect is due to stres s.

Activity indices suggest that the changes in

catecholarnines rnay produce behavioral changes in these animals.
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APPENDIX

58a

1 Day
NE
n /brain)

14 Days
DA
(n /brain)

NE
(n /brain)

DA
(n /brain)

236

621

219

661

248

573

227

623

229

654

240

602

225

642

222

612

Table I.

The Effects of Freezing on Brain Catecholamine Levels.

59

Treatment

SC

DAMS

UC

Day
0

1. 27 +0. 09( 40)

1. 27 +0. 13 (40)

1. 32+0. 10(38)

3

1.85+0.09(29)

2. 1 0 +0. 4 7 ( 28)

2. 14+0. 26 (35 )

7

3.96+0.59(16)

4. 14 +0. 4 7 ( 15 )

4. 05 +0. 97 ( 1 5 )

14

8. 33 +0. 39 ( 14)

7. 99+0. 94( 1 0)

7.47+1.32(12)

21

10.00+1.1S(11)

10. 1 7 + 1. 45 ( 10)

9. 79 + 1. 1 9( 14)

30

16.77+1.49(11)

17.53+2. 58(S}

16.22+2.76(18)

Mean + S. D. M. (N)

Table II.

Body Weights in Gram.s from Birth to 30 Days of Age for

Pups Used in the Biochem.ical Study.

60

DAMS

SC

UC

0

.086

.087

.090

3

. 130

. 137

.139

7

.236

.222

.246

14

.376

.382

.373

21

.399

.400

.399

30

.419

.423

. 412

Treatment

Da

Table III.

Brain Weights in Grams from Birth to 30 Days of Age

for Pups Used in the Biochemical Study.
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Treatnlent

UC

SC

DAMS

I

Day

I
,t.......,..

0

5. 2 2 + 1. 1 2 'I" ~I" 5 )
(

9.81+1.79(8)

11.68+1.62(5)

3

19.12+7.72(7)

23. 8 9 +8. 8 9 ( 6 )

22.48+5.91(7)

7

36. 5 9 + 1 3. 3.0 (4)

36.30+2. II(5)

41. 88+7.54(6)

14

75. 8 1 +9. 0 1 ( 6 )

73. 5 0 +5. 07 ( 3 )

87.34+10.41(5)

21

116.28+14.89(6)

130. 95+3. 35",1" (5)

30

290.41+54.33**(6)

1 78. 8 4 +5 1 • 40 ..... (6 )

..I"

96.65+19.03(6)

..f",

*(p

Mean + S. D. M. (N)
....r....

,t.-.

~I""'"

Table IV.

(p

<

• 01)

<

• 001)

Nanograms of Norepinephrine per Brain.

133. 55 +47. 45 (12)

Table V. Nanograms of Norepinephrine per Gram Brain. The levels
of norepinephrine per gram wet weight of brain increased gradually
with time.

The group effect was significant at the p < • 05 level and

the group by time interaction was significant at the p < • 01 level.

62a

DP.. MS

SC

DC

0

62.50

115.20

133.34

3

144. 31

170.30

158.68

7

157. 48

161.82

175.24

14

202.71

195.80

235.27

21

294.02

328.72

242.42

30

650.88

431.17

324.99

Treatment
Day

Table V.

Nanogra:ms of Norepinephrine per Gram Brain.
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Treatment

DAMS

UC

SC

~
0

18.93+9.9 1 (5)

12.34+5.91(8)

14. 75 +6. 89 (4)

3

13.91+11.21(7)

23.59+10.28(6)

2 1. 3 7 +6. 5 1 ( 6 )

7

I 45.80+18.70(4)

49. 32 +6. 80(5)

61.46+14.63(6)

167 • 0 7+20.42(6)

132.00+15.59(3)

178.76+28.40(5)

21

288.23+80.65(6)

3 74. 8 9 + 1 5. 6 5

30

5 5 8. 2 8 + 1 5 8. 7 5 ~:~ :::~ {6 )

454.69+92.08:::\6 )

14

1

Mean

+

~I' ~I"I'(

5)

~:, (p

<

• 05)

):~ ~:~ ( p

<

• 01)

<

•

S. D. M. (N)

...1.........,

~ ....

~'''I "(

Table VI.

.... 1, ...... ,............

P

Nanograms of Dopamine per Brain.

001)

454.69+92.08(6)
301.61+136.60(12)

Table VII.

Nanograms of Dopamine per Gram Brain.

The levels of

dopamine per gram wet weight of brain follow the same pattern as
those of the whole brain.

They are also parallel to but higher than the

levels of norepinephrine per gram brain.

The group effect was sig-

nificant at the p < • 05 level and the group by time interaction was
significant at the p < • 01 level.

64a

~c }·l'~~ltn1.C

nt

DAMS

SC

DC

Day

0

223.93

143.21

162.99

3

103.24

168.02

155.36

7

197.51

218.71

256.57

14

445.38

349.67

480.00

21

727.19

940.52

634.28

30

1338.14

1095.32

730. 11

Table VII.

Nanograms of Dopamine per Gram Brain.
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sc

DAMS

Treatment
Male

Female

Male

Female

12

123.0

126.7

149.0

163.3

15

95.8

99. 5

130. 1

144.4

93. 5

97.2

112.4

126.6

107. 1

110. 8

113. 9

128.2

131.2

134.8

136. 5

150.8

Sex
Day

118

I

II

121
130
Table VIII.

!

Jiggle Platform Scores.

ERRATA

Page 37, line 17. hormone.

-

Page 63. day 21, UC. 254.69+92.08(6).
,

Page 2a. 3-methoxydopamine should be 3-0-methyl dopamine.

